The DETOUR2 Clinical Study
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03119233|
Recruitment Status : Active, not recruiting
First Posted : April 18, 2017
Last Update Posted : March 21, 2023
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
|Condition or disease||Intervention/treatment||Phase|
|Peripheral Arterial Disease||Device: PQ Bypass System||Not Applicable|
The DETOUR2 study is a prospective, single-arm, multi-center, international, non-randomized, safety and effectiveness clinical investigation of the PQ Bypass system.
The PQ Bypass System is intended to improve blood flow in patients with symptomatic peripheral arterial disease due to symptomatic femoropopliteal chronic total occlusions ≥ 20 cm (TASC D) that can include de novo, restenotic, or in-stent restenotic lesions; or Symptomatic femoropopliteal lesions ≥ 24 cm (total lesion length) that can include a chronic total occlusion or a ≥70% lesion that includes de novo, restenotic or in-stent restenosis (complex TASC C), with reference vessel diameters ranging from 5.0 - 6.7 mm, by investigator visual assessment.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||220 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||The Detour Endovascular Technique for Long OcclUsive Fem-pop Revascularization - 2 Clinical Trial|
|Actual Study Start Date :||December 13, 2017|
|Actual Primary Completion Date :||December 22, 2021|
|Estimated Study Completion Date :||November 23, 2023|
The PQ Bypass system is used during a minimally invasive procedure to place stent grafts in the peripheral vasculature to improve blood flow.
Device: PQ Bypass System
Intended use from CLN114 Rev F (CLN114 is the DETOUR2 protocol) The PQ Bypass System is intended to improve blood flow in patients with peripheral arterial disease in symptomatic femoropopliteal lesions due to chronic total occlusions ≥ 20 cm (TASC D) that can include de novo, restenotic, or in-stent restenotic lesions; or total lesion lengths ≥24 cm that can include chronic total occlusions or a ≥70% lesion that includes de novo, restenotic or in-stent restenosis (complex TASC C).
- Primary Effectiveness Endpoint [ Time Frame: 12 months ]The absence of clinically-driven target lesion revascularization and/or absence of recurrent target lesion diameter stenosis >50% by imaging (e.g., duplex ultrasound (peak systolic velocity ratio of >2.5) or invasive angiography) with the stent or immediately 1 cm above or below the treated segment.). When both modalities are available, angiography takes precedence.
- Primary Safety Endpoint [ Time Frame: 30 days ]Freedom from a major adverse event (MAE) at 30 days post-procedure defined as any occurrence of the following events: Death, Clinically-Driven Target Lesion Revascularization (CD-TLR), Major Amputation of(above the Treated Limb,ankle), Symptomatic Deep Vein Thrombosis (DVT), Pulmonary Embolism, or procedure-related bleeding requiring any transfusion of packed red blood cells or surgery.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years to 90 Years (Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
All subjects are required to meet the following inclusion criteria in order to be considered eligible for participation in the study:
General Inclusion Criteria
- Age > 18 and ≤ 90 years of age.
- Willing and able to provide informed consent.
Subject is willing to undergo all follow-up assessments according to the specified schedule over 36 months.
Clinical Inclusion Criteria
- Chronic, symptomatic lower limb ischemia defined as Rutherford clinical categories 3, 4, or 5.
- Venous Clinical Severity Score < 3.
Subject is a suitable candidate for angiography and endovascular intervention and, if required, is eligible for standard surgical repair.
Angiographic Inclusion Criteria
- Symptomatic femoropopliteal chronic total occlusions ≥ 20 cm (TASC D) that can include de novo, restenotic, or in-stent restenotic lesions; or Symptomatic femoropopliteal lesions ≥ 24 cm (total lesion length) that can include a chronic total occlusion or a ≥70% lesion that includes de novo, restenotic or in-stent restenosis (complex TASC C), by investigator visual assessment.
- Reference vessel diameter ≥ 4.5 and ≤ 6.7 mm, by investigator visual assessment.
- Subject has a patent popliteal artery (<50% stenosis) distal to the landing zone
- Able to successfully access the SFA origin for entry of the crossing device.
- At least one patent infrapopliteal vessel (<50% stenosis) with run-off to the ankle or foot.
- A significant stenosis (≥ 50%) or occlusion of an ipsilateral, inflow artery (e.g. aortoiliac, common femoral) must be successfully treated (use of investigational treatment prohibited) prior to treatment of the target lesion. Successful treatment is defined as no complications and less than 30% residual stenosis following intervention.
General Exclusion Criteria
- Participating in another investigational clinical study.
- Anticipated life expectancy less than 1 year or medical comorbid condition(s) that could limit the subject's ability to comply with the requirements of the trial.
Subject has other medical, social or psychological problems that, in the opinion of the investigator, preclude them from receiving this treatment, and the procedures and evaluations pre- and post-treatment.
Clinical Exclusion Criteria
- History of deep vein thrombosis on either limb.
- Thrombophlebitis, within the previous 30 days.
- 6. Planned major amputation of the target limb, including minor amputation (above the ankle).
- Prior distal amputation (above the transmetatarsal) of the target limb.
- Known or suspected active infection at the time of the procedure (e.g., WIfI foot infection grade 3: Severe infection. Local infection with systemic inflammatory response syndrome [SIRS])
- Rutherford clinical category 0, 1, 2 or 6.
- Has acute or chronic renal disease with GFR ≤ 30 ml/min per 1.73 m2 and/or elevated serum creatinine >2.5mg/dL (220µmol/L) or on dialysis.
- Known hypersensitivity/allergy to the investigational devices and/or required pharmacotherapy that cannot be safely managed.
- Morbid obesity that does not allow for safe vascular access or imaging.
- Subject has a known coagulopathy or has bleeding diatheses, thrombocytopenia with platelet count less than 100,000/microliter or INR > 1.8.
- Requires coronary or peripheral procedure within 30 days prior to or planned within 30 days post treatment of the target lesion.
- Has a known history of intracranial bleeding or aneurysm, myocardial infarction or stroke within the last 3 months.
- Subject is pregnant or breast-feeding. Angiographic Exclusion Criteria
- Stent within 3 cm of SFA ostium.
- Previous bypass surgery on the target limb.
- Subject has significant disease or obstruction (≥50%) of the inflow tract that has not been successfully treated at the time of the index procedure (success measured as ≤30% residual stenosis, without complication)
- Presence of aneurysm or acute thrombus in the target limb.
- Thrombolysis of the target vessel within 72 hours prior to the index procedure, where complete resolution of the thrombus was not achieved.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03119233
|Principal Investigator:||Jihad Mustapha, MD||Advanced Cardiac and Vascular Amputation Prevention Centers|
|Principal Investigator:||Sean Lyden, MD||The Cleveland Clinic|
|Responsible Party:||PQ Bypass, Inc.|
|Other Study ID Numbers:||
|First Posted:||April 18, 2017 Key Record Dates|
|Last Update Posted:||March 21, 2023|
|Last Verified:||March 2023|
|Individual Participant Data (IPD) Sharing Statement:|
|Plan to Share IPD:||No|
|Studies a U.S. FDA-regulated Drug Product:||No|
|Studies a U.S. FDA-regulated Device Product:||Yes|
|Device Product Not Approved or Cleared by U.S. FDA:||Yes|
Peripheral Arterial Disease
Peripheral Vascular Diseases
Arterial Occlusive Diseases